| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
164.20(B) |
| Last
Volume: |
2,739,780 |
Avg
Vol: |
2,731,367 |
| 52
Week Range: |
$258.59 - $337.38 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 442 |
| Guru Rank Value : 4.5 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,500 |
82,576 |
82,576 |
106,347 |
| Total Sell Value |
$714,210 |
$24,503,370 |
$24,503,370 |
$30,974,890 |
| Total People Sold |
2 |
8 |
8 |
8 |
| Total Sell Transactions |
2 |
10 |
10 |
14 |
| End Date |
2025-03-27 |
2024-12-24 |
2024-06-25 |
2023-06-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Khosla Rachna |
SVP, Business Development |
• • – |
2025-06-05 |
4 |
S |
$289.68 |
$434,520 |
D/D |
(1,500) |
8,162 |
|
3% |
|
| Miles Amy E |
Director |
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
4,842 |
|
- |
|
| Holley Charles M |
Director |
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
11,237 |
|
- |
|
| Ishrak Omar |
Director |
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
6,084 |
|
- |
|
| Drake Michael V |
Director |
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
4,547 |
|
- |
|
| Jacks Tyler |
Director |
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
17,193 |
|
- |
|
| Garland Greg C. |
Director |
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
13,183 |
|
- |
|
| Eckert Robert |
Director |
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
25,027 |
|
- |
|
| Druker Brian |
Director |
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
7,569 |
|
- |
|
| Austin Wanda M |
Director |
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
7,353 |
|
- |
|
| Kullman Ellen Jamison |
Director |
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
13,467 |
|
- |
|
| Klotman Mary E. |
Director |
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
1,528 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
610 |
9,662 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,311 |
413,499 |
|
- |
|
| Griffith Peter H. |
EVP & CFO |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,919 |
42,246 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
961 |
10,189 |
|
- |
|
| Reese David M |
EVP & Chief Technology Officer |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,549 |
42,116 |
|
- |
|
| Drake Michael V |
Director |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
129 |
3,738 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,327 |
76,367 |
|
- |
|
| Bradner James E. |
EVP, R&D, & Chief Sci. Officer |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,549 |
29,753 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
591 |
8,463 |
|
- |
|
| Holley Charles M |
Director |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
157 |
10,428 |
|
- |
|
| Graham Jonathan P |
EVP & Gen. Counsel & Secy. |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,180 |
33,517 |
|
- |
|
| Busch Matthew C. |
VP, Finance & CAO |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
554 |
4,588 |
|
- |
|
| Ishrak Omar |
Director |
• • – |
2025-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
129 |
5,275 |
|
- |
|
915 Records found
|
|
Page 1 of 37 |
|
|
2.86 (1.03%) 
